Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.2K
Overview
51.2K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

334
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
334
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

194
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
194
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

225
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
225
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.8K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Retrospective cohort study of mRNA COVID-19 vaccine-associated enhanced disease in the Vaccine Safety Datalink, 2021-23.

Human vaccines & immunotherapeutics·2026
Same author

Effects of age and birth cohort on influenza A virus subtype-specific hospitalization rates, United States 2010-2025.

The Journal of infectious diseases·2026
Same author

Influenza Antibody Levels Associated with Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu VE Network, November 2018-May 2019.

medRxiv : the preprint server for health sciences·2026
Same author

Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season.

medRxiv : the preprint server for health sciences·2026
Same author

Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.

MMWR. Morbidity and mortality weekly report·2026

Related Experiment Video

Updated: Jan 15, 2026

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

8.5K

Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations.

Edward A Belongia1, Huong Q Nguyen1, David L McClure1

  • 1Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|October 8, 2025
PubMed
Summary

New influenza vaccines aim for broader, longer protection. Evaluating their effectiveness requires careful consideration of comparative studies, especially given challenges with vaccine uptake.

Keywords:
influenzapolicyrelative effectivenessstudy designvaccine

More Related Videos

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

37.7K
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

8.1K

Related Experiment Videos

Last Updated: Jan 15, 2026

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

8.5K
An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

37.7K
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

8.1K

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • New influenza vaccines are anticipated, aiming for improved cross-reactivity and duration of protection.
  • Current recommendations rely on effectiveness evaluations, necessitating robust methodologies for novel vaccines.

Purpose of the Study:

  • To discuss considerations for evaluating the comparative effectiveness of new influenza vaccines.
  • To highlight the importance of absolute and relative vaccine effectiveness (rVE) assessments.

Main Methods:

  • Review of methodologies for assessing vaccine effectiveness, including clinical trials, cluster-randomized trials, and observational designs.
  • Discussion of the advantages and limitations of different study designs for rVE.

Main Results:

  • Cluster-randomized trials offer reduced bias but face operational challenges.
  • Observational studies provide timely and cost-effective rVE data but struggle with variable vaccine uptake.

Conclusions:

  • Comparative effectiveness evaluations are crucial for informing recommendations on new influenza vaccines.
  • Addressing challenges in assessing rVE, particularly variable uptake, is essential for real-world application.